HomeAboutRankingsData Sources
Β© 2026 GeneE
🧬
GeneE
10 sources retrieved Β· Most recent: April 2026 Β· Index updated 14 days ago
β“˜GeneE is for informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.
COL13A1
collagen type XIII alpha 1 chain
Chromosome 10 Β· 10q22.1
NCBI Gene: 1305Ensembl: ENSG00000197467.17HGNC: HGNC:2190UniProt: A0A2R8YGI3
49PubMed Papers
21Diseases
0Drugs
44Pathogenic Variants
CLINICAL
OMIM Disease Gene
DATA QUALITY
βœ“ Experimental GO Evidenceβœ“ Swiss-Prot Reviewed
cell-matrix adhesionheparin bindingcell-cell adhesionprotein bindingCongenital myasthenic syndromestype 2 diabetes mellitusPostsynaptic congenital myasthenic syndromespostsynaptic congenital myasthenic syndrome
✦AI Summary

COL13A1 encodes collagen type XIII alpha 1 chain, a transmembrane collagen with a cytosolic domain, transmembrane region, and collagenous ectodomain 1. The gene is located on chromosome 10 and contains 42 exons spanning approximately 135 kilobases 1. Primary Function: COL13A1 mediates cell-matrix and cell-cell adhesion interactions essential for normal development 2. It may participate in muscle fiber-basement membrane linkage and endochondral bone ossification 2. At neuromuscular junctions, COL13A1 plays a role in acetylcholine receptor clustering 2. In pancreatic islet endothelial cells, COL13A1 functions as a structural gene component of the vascular microenvironment 3. Mechanism: COL13A1-expressing cancer-associated fibroblasts produce chemokines that recruit macrophages and regulatory T cells while limiting dendritic cell and T cell recruitment 4. Cancer cells produce COL13A1 to promote tumor budding and invasion through invadopodia formation 5. COL13A1 expression is downregulated by the EP2 receptor agonist omidenepag in trabecular meshwork cells, contributing to aqueous humor outflow enhancement 6. Disease Relevance: Pathogenic variants in COL13A1 cause congenital myasthenic syndrome (CMS), characterized by impaired neuromuscular signal transmission 2. COL13A1 variants associate with elevated transaminase levels and non-alcoholic fatty liver disease risk in admixed Mexican populations 7.

Sources cited
1
COL13A1 is one of 35 genes implicated in congenital myasthenic syndromes; role in acetylcholine receptor clustering at neuromuscular junctions
PMID: 36835142
2
COL13A1 gene structure: 135 kb, 42 exons; transmembrane protein with cytosolic domain, transmembrane region, and collagenous ectodomain; located on chromosome 10
PMID: 10429945
3
COL13A1 identified as structural gene in islet-specific endothelial cells in human pancreatic tissue
PMID: 39915484
4
COL13A1-expressing cancer-associated fibroblasts produce chemokines affecting immune cell recruitment in NSCLC
PMID: 37285399
5
COL13A1 produced by cancer cells promotes tumor budding and invasion in urothelial carcinoma through invadopodia formation
PMID: 28415608
6
COL13A1 expression is downregulated by omidenepag in trabecular meshwork cells, contributing to IOP-lowering mechanism in glaucoma
PMID: 36630412
7
COL13A1 variants (rs1227756) associated with elevated transaminase levels and NAFLD risk in Mexican populations
PMID: 29307798
8
Congenital myasthenic syndromes caused by COL13A1 represent rare NMD subtype in Lebanese population cohort
PMID: 34602496
Disease Associationsβ“˜21
Congenital myasthenic syndromesOpen Targets
0.75Strong
type 2 diabetes mellitusOpen Targets
0.40Weak
Postsynaptic congenital myasthenic syndromesOpen Targets
0.38Weak
postsynaptic congenital myasthenic syndromeOpen Targets
0.38Weak
congenital myasthenic syndromeOpen Targets
0.37Weak
presynaptic congenital myasthenic syndromeOpen Targets
0.37Weak
Presynaptic congenital myasthenic syndromesOpen Targets
0.37Weak
placenta praeviaOpen Targets
0.36Weak
protozoa infectious diseaseOpen Targets
0.33Weak
sensorineural hearing lossOpen Targets
0.33Weak
disorder of earOpen Targets
0.33Weak
systemic lupus erythematosusOpen Targets
0.32Weak
placental retentionOpen Targets
0.29Weak
Abnormality of the gastrointestinal tractOpen Targets
0.29Weak
Nasal polyposisOpen Targets
0.28Weak
narcolepsyOpen Targets
0.27Weak
exostosisOpen Targets
0.27Weak
diabetic ketoacidosisOpen Targets
0.27Weak
neuroendocrine neoplasmOpen Targets
0.26Weak
skin diseaseOpen Targets
0.24Weak
Myasthenic syndrome, congenital, 19UniProt
Pathogenic Variants44
NM_001368882.1(COL13A1):c.769_803del (p.Ser257fs)Pathogenic
not provided|Congenital myasthenic syndrome 19
β˜…β˜…β˜†β˜†2026β†’ Residue 257
NM_001368882.1(COL13A1):c.1285-1G>CLikely pathogenic
not provided|Congenital myasthenic syndrome 19
β˜…β˜…β˜†β˜†2026
NM_001368882.1(COL13A1):c.709C>T (p.Arg237Ter)Pathogenic
Congenital myasthenic syndrome 19|not provided
β˜…β˜…β˜†β˜†2025β†’ Residue 237
NM_001368882.1(COL13A1):c.435+2T>GLikely pathogenic
not provided
β˜…β˜…β˜†β˜†2025
NM_001368882.1(COL13A1):c.513del (p.Gly172fs)Pathogenic
Congenital myasthenic syndrome 19
β˜…β˜…β˜†β˜†2024β†’ Residue 172
NM_001368882.1(COL13A1):c.1026+1G>ALikely pathogenic
Congenital myasthenic syndrome 19|not provided
β˜…β˜…β˜†β˜†2024
NM_001368882.1(COL13A1):c.967-2A>GLikely pathogenic
not provided|Congenital myasthenic syndrome 19
β˜…β˜…β˜†β˜†2024
NM_001368882.1(COL13A1):c.648del (p.Gly217fs)Pathogenic
not provided|Congenital myasthenic syndrome 19
β˜…β˜…β˜†β˜†2023β†’ Residue 217
NM_001368882.1(COL13A1):c.76del (p.Val26fs)Pathogenic
not provided
β˜…β˜†β˜†β˜†2026β†’ Residue 26
NM_001368882.1(COL13A1):c.1220_1221insT (p.Gly408fs)Pathogenic
not provided
β˜…β˜†β˜†β˜†2025β†’ Residue 408
NM_001368882.1(COL13A1):c.330_354del (p.Pro111fs)Pathogenic
not provided
β˜…β˜†β˜†β˜†2025β†’ Residue 111
NM_001368882.1(COL13A1):c.1284+1G>ALikely pathogenic
not provided
β˜…β˜†β˜†β˜†2025
NM_001368882.1(COL13A1):c.362dup (p.Gly122fs)Pathogenic
not provided
β˜…β˜†β˜†β˜†2025β†’ Residue 122
NM_001368882.1(COL13A1):c.1230+1G>ALikely pathogenic
not provided
β˜…β˜†β˜†β˜†2025
NM_001368882.1(COL13A1):c.658-1G>CLikely pathogenic
not provided
β˜…β˜†β˜†β˜†2024
NM_001368882.1(COL13A1):c.1288G>T (p.Glu430Ter)Pathogenic
not provided
β˜…β˜†β˜†β˜†2024β†’ Residue 430
NM_001368882.1(COL13A1):c.55_62del (p.Glu19fs)Pathogenic
not provided
β˜…β˜†β˜†β˜†2024β†’ Residue 19
NM_001368882.1(COL13A1):c.685-1223G>CLikely pathogenic
not provided
β˜…β˜†β˜†β˜†2024
NM_001368882.1(COL13A1):c.1914+1G>ALikely pathogenic
not provided
β˜…β˜†β˜†β˜†2024
NM_001368882.1(COL13A1):c.1230+1G>CLikely pathogenic
not provided
β˜…β˜†β˜†β˜†2023
View on ClinVar β†—
Related Genes
COLGALT2Protein interaction96%COL4A2Protein interaction80%P4HA1Protein interaction79%COL16A1Protein interaction78%PLOD3Protein interaction76%COL27A1Protein interaction70%
Tissue Expression

No tissue expression data available for this gene.

Gene Interaction Network
Click a node to explore
COL13A1COLGALT2COL4A2P4HA1COL16A1PLOD3COL27A1
PROTEIN STRUCTURE
Preparing viewer…
AlphaFoldAI-predicted Β· UniProt Q5TAT6
View on AlphaFold β†—
Constraintβ“˜
LOEUFβ“˜
0.89LoF Tolerant
pLIβ“˜
0.00Tolerant
Observed/Expected LoF0.73 [0.61–0.89]
RankingsWhere COL13A1 stands among ~20K protein-coding genes
  • #8,929of 20,598
    Most Researched49
  • #1,447of 5,498
    Most Pathogenic Variants44
  • #7,913of 17,882
    Most Constrained (LOEUF)0.89
Genes detectedCOL13A1
Sources retrieved10 papers
Response timeβ€”
πŸ“„ Sources
10β–Ό
1
Clinical and Pathologic Features of Congenital Myasthenic Syndromes Caused by 35 Genes-A Comprehensive Review.
PMID: 36835142
Int J Mol Sci Β· 2023
1.00
2
A 20-year Clinical and Genetic Neuromuscular Cohort Analysis in Lebanon: An International Effort.
PMID: 34602496
J Neuromuscul Dis Β· 2022
0.90
3
Single-cell atlas of human pancreatic islet and acinar endothelial cells in health and diabetes.
PMID: 39915484
Nat Commun Β· 2025
0.80
4
Tumor-associated fibrosis impairs immune surveillance and response to immune checkpoint blockade in non-small cell lung cancer.
PMID: 37285399
Sci Transl Med Β· 2023
0.70
5
Downregulation of COL12A1 and COL13A1 by a selective EP2 receptor agonist, omidenepag, in human trabecular meshwork cells.
PMID: 36630412
PLoS One Β· 2023
0.60